Triamterene/hydrochlorothiazide is a combination blood pressure pill that pairs two diuretics with opposing effects on potassium. Hydrochlorothiazide (often shortened to HCTZ) lowers blood pressure by making the kidneys excrete more sodium and water, but it drags potassium out with them. Triamterene blocks potassium loss in a different part of the kidney. Putting them together in one tablet gives you the blood pressure reduction of a thiazide with a built-in guard against one of its most common side effects. The combination has been prescribed since the 1960s, and while newer drug classes have taken the spotlight, it remains one of the most widely filled generic prescriptions in the United States.
How the Two Drugs Work Together
Hydrochlorothiazide acts on a specific sodium transporter in the kidney’s distal convoluted tubule, blocking sodium reabsorption. When sodium stays in the urine, water follows, which reduces blood volume and lowers blood pressure. The problem is that when more sodium reaches the collecting duct downstream, the kidney swaps it for potassium, pushing potassium into the urine. Triamterene plugs that exchange. It blocks a sodium channel in the collecting duct, so less sodium gets reabsorbed there and less potassium gets dumped. The net result is that the body still sheds sodium and water but holds on to more potassium than it would with HCTZ alone.
Triamterene also contributes a modest additional drop in blood pressure beyond what HCTZ achieves on its own. A large observational analysis found that adding triamterene to HCTZ lowered systolic blood pressure by roughly 1 to 4 mmHg more than HCTZ alone, depending on what other medications the patient was taking.1Springer Link / PubMed Central. Triamterene Enhances the Blood Pressure Lowering Effect of Hydrochlorothiazide in Patients with Hypertension That may not sound dramatic, but at a population level, even small sustained reductions in blood pressure translate into fewer strokes and heart attacks over time.
The Potassium Problem It Was Designed to Solve
Thiazide-induced low potassium (hypokalemia) is not just a lab curiosity. It can cause muscle cramps, weakness, heart rhythm disturbances, and fatigue. In one study of patients taking 50 mg of HCTZ daily, about a third had potassium levels that had dropped below the normal floor of 3.5 mEq/L. When those patients were switched to the triamterene/HCTZ combination, their average potassium climbed from 3.56 to 4.17 mEq/L within two to three weeks, and the improvement held steady for more than a year of follow-up.2PubMed. Outpatient conversion of treatment to potassium-sparing diuretics A separate trial confirmed that higher thiazide doses amplified the drop in both potassium and magnesium, and that triamterene effectively blocked those losses.3PubMed. Antihypertensive and biochemical effects of different doses of hydrochlorothiazide alone or in combination with triamterene
This potassium-sparing property is the main reason the combination exists. For patients who need a thiazide but repeatedly develop low potassium despite dietary adjustments, the fixed-dose combination avoids the hassle of taking a separate potassium supplement or a standalone potassium-sparing drug.
Not All Tablets Are Created Equal
If you have been around long enough, you may remember two brand names: Dyazide (a capsule) and Maxzide (a tablet). These were not interchangeable, and the reason mattered clinically. Dyazide capsules delivered considerably less of both active ingredients into the bloodstream than Maxzide tablets. Pharmacokinetic studies showed that the hydrochlorothiazide in Dyazide was only about two-thirds as bioavailable as in Maxzide, and the triamterene was roughly half as bioavailable.4PubMed. Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: influence of age and renal function A separate urinary-recovery study found essentially the same pattern: only about half as much HCTZ and triamterene showed up in the urine after Dyazide compared to the newer tablet formulation.5PubMed. Bioequivalence study of a new tablet formulation of triamterene and hydrochlorothiazide
This meant that two Dyazide capsules did not equal one Maxzide tablet, even though a prescriber might assume they were close enough. A head-to-head comparison confirmed the clinical relevance: the two formulations were not equivalent for blood pressure control at doses that looked similar on paper.6PubMed. A comparison of the anti-hypertensive effectiveness of two triameterene/hydrochlorothiazide combinations: Maxzide versus Dyazide Today, most generic versions use the tablet formulation with improved bioavailability, but the history is a useful reminder that “same ingredients” does not always mean “same drug delivery.”
Blood Pressure Lowering in Practice
In a clinical trial of patients with mild hypertension, four weeks on triamterene 37.5 mg/HCTZ 25 mg dropped average blood pressure from about 145/95 to 130/85 mmHg, a reduction of roughly 15/10 mmHg. About 60% of patients met the study’s definition of a responder at that dose. Those who did not respond were bumped to the higher-strength version (triamterene 75 mg/HCTZ 50 mg), and that group saw further blood pressure decreases.7PubMed. Efficacy and safety of triamterene/hydrochlorothiazide combinations in mild systemic hypertension
Beyond just numbers on a blood pressure cuff, the combination has shown evidence of reducing actual cardiovascular events. A review of diuretic-based trials noted that triamterene/HCTZ outperformed placebo for reducing cardiovascular events in elderly European patients.8PubMed. Not just chlorthalidone: evidence-based, single tablet, diuretic alternatives to hydrochlorothiazide for hypertension That is worth noting because HCTZ on its own has long been criticized for having less cardiovascular outcome data than its cousin chlorthalidone. The combination with triamterene partially addresses that gap.
Metabolic Side Effects Worth Knowing About
Thiazide diuretics as a class nudge blood sugar upward. A systematic review and meta-analysis of randomized trials found that thiazide-type diuretics raised fasting blood glucose by a small but real amount, on average about 5 mg/dL compared to non-thiazide treatments or placebo.9PubMed Central. Association of Thiazide-Type Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials Animal research has probed the mechanism, linking HCTZ exposure to impaired glucose tolerance through changes in the gut microbiome and downstream inflammatory pathways.10PubMed Central. Hydrochlorothiazide-induced glucose metabolism disorder is mediated by the gut microbiota via LPS-TLR4-related macrophage polarization
Here is where potassium-sparing diuretics may offer a partial rescue. The PATHWAY-3 trial directly compared HCTZ alone to amiloride alone and to the combination. Patients on amiloride (a potassium-sparing diuretic similar in function to triamterene) had better glucose tolerance than those on HCTZ alone, and the combination also performed better than HCTZ alone on glucose measures.11The Lancet. Comparison of single and combination diuretics on glucose tolerance in patients with hypertension (PATHWAY-3) The working theory is that low potassium itself impairs insulin secretion, so keeping potassium in a normal range blunts the metabolic hit. That is one more reason the triamterene component earns its place in the pill.
Thiazides also raise uric acid levels, which over time can trigger gout. A systematic review found that diuretic users face a higher risk of gouty arthritis than non-users, and one trial specifically measuring triamterene/HCTZ against placebo found a substantially elevated rate ratio for gout.12PubMed. Use of diuretics and the risk of gouty arthritis: a systematic review If you have a history of gout or consistently high uric acid, this combination may not be the best diuretic option for you, and your doctor should consider alternatives.
Low Sodium and Who Is Most Vulnerable
Thiazide-induced low sodium (hyponatremia) is the electrolyte disturbance that lands people in the emergency department. It usually shows up within the first two weeks of starting the drug, though it can develop later if something changes, such as adding a new medication, getting a stomach illness, or simply aging. Risk factors include older age, female sex, low body weight, and concurrent use of other drugs that affect water balance, such as certain antidepressants.13PubMed Central. Thiazide-induced hyponatremia
The combination of a thiazide with an SSRI antidepressant is a particularly risky pairing for hyponatremia. Both drug classes can independently impair the kidney’s ability to excrete dilute urine, and together they amplify the problem.14The American Journal of the Medical Sciences. Severe Hyponatremia Associated With Combined Thiazide Diuretic and Serotonin Reuptake Inhibitor Therapy If you are over 65, thin, female, and taking an SSRI alongside triamterene/HCTZ, your doctor should be checking your sodium levels regularly, especially in the first month.
Kidney Stones and Kidney Inflammation
This is an underappreciated quirk of triamterene: it can crystallize in the urine and serve as the seed for kidney stones. Most kidney stones are made of calcium or uric acid. Triamterene stones are rare, but they are a recognized drug-induced cause of urinary calculi.15PubMed Central. Drug-induced urinary calculi In extreme cases, those crystals can precipitate inside the kidney’s tubules and cause acute kidney injury.16PubMed. Crystal-induced acute renal failure Staying well hydrated while taking the drug is the simplest way to reduce this risk, because dilute urine is far less likely to allow crystal formation.
Separately, the combination has been linked to a rare allergic-type kidney reaction called acute interstitial nephritis. In case series, patients developed kidney failure five to ten weeks after starting the drug, with biopsies showing intense inflammation in the kidney tissue. In all reported cases, stopping the medication led to full or near-full recovery of kidney function.17The American Journal of Medicine. Acute Interstitial Nephritis Due to Hydrochlorothiazide-Triamterene Therapy Some biopsies even revealed granulomas, which are clumps of immune cells characteristic of a hypersensitivity reaction.18PubMed. Drug-induced acute interstitial nephritis with granulomas This reaction is unusual enough that most patients will never encounter it, but a new onset of unexplained fever and rising creatinine in someone recently started on the drug should raise a red flag.
Interactions With Common Medications
The interaction that matters most in day-to-day practice involves painkillers. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen reduce blood flow to the kidneys. Diuretics do the same thing by lowering blood volume. Combine the two during a situation that further stresses kidney perfusion, such as heavy exercise or dehydration, and you can tip a healthy kidney into acute failure. A case report documented exactly that scenario: a patient on HCTZ/triamterene developed severe acute kidney injury after strenuous exercise while also taking ibuprofen at standard doses.19PubMed. Exercise-induced acute renal failure associated with ibuprofen, hydrochlorothiazide, and triamterene The practical takeaway is straightforward: if you are on this combination, reach for acetaminophen instead of ibuprofen when you need a painkiller, especially around vigorous physical activity or in hot weather.
The other major interaction category involves drugs that raise potassium. ACE inhibitors (like lisinopril) and ARBs (like losartan) both reduce potassium excretion. Add a potassium-sparing diuretic like triamterene on top, and you theoretically stack two potassium-raising mechanisms. A review of RAAS-blocker interactions flagged this combination as a potential hyperkalemia risk.20PubMed Central. An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers That said, a real-world cohort study using electronic health records found that concurrent use of potassium-sparing diuretics with ACE inhibitors or ARBs produced only very small increases in serum potassium that were likely not clinically meaningful, and there was no significant increase in the odds of frank hyperkalemia.21JAPhA Pharmacotherapy. Changes in serum potassium with concomitant administration of renin-angiotensin system agents and potassium-sparing diuretics So the combination is used in practice, but periodic potassium monitoring makes sense, especially for people with reduced kidney function or diabetes.
Skin Cancer Concerns With Long-Term HCTZ Use
Over the past several years, regulatory agencies have flagged a possible link between long-term HCTZ use and nonmelanoma skin cancer, particularly squamous cell carcinoma. HCTZ is a known photosensitizer, meaning it makes skin more vulnerable to UV damage. A Dutch cohort study found that very high cumulative HCTZ exposure (the equivalent of more than 13 years of daily use) was associated with substantially elevated rates of skin cancer, especially squamous cell carcinoma.22PubMed Central. Chronic Use of Hydrochlorothiazide and Risk of Skin Cancer in Caucasian Adults: A PharmLines Initiative Inception Cohort Study However, the picture is not straightforward. A large U.S. population-based analysis that accounted for personal risk factors found no meaningful increase in nonmelanoma skin cancer risk among HCTZ users compared to those on ACE inhibitors across commercial and health-risk-assessment cohorts.23PubMed. Skin Cancer and Hydrochlorothiazide: Novel Population-Based Analyses Considering Personal Risk Factors Including Race/Ethnicity
The discrepancy between European and U.S. findings may partly reflect differences in UV exposure, skin type distribution, and how well the studies controlled for sun habits. For now, the practical advice is common-sense sun protection: wear sunscreen and limit prolonged UV exposure if you are on any HCTZ-containing medication, particularly if you are fair-skinned and expect to take the drug for many years. This concern applies to the HCTZ component specifically and would be the same whether you take HCTZ alone or in combination with triamterene.
Use During Pregnancy
Diuretics during pregnancy are generally avoided because reducing blood volume could theoretically compromise blood flow to the placenta. That said, the evidence base is more reassuring than most people expect. A meta-analysis covering nearly 7,000 newborns exposed to diuretics in utero did not find an increased risk of birth defects, growth restriction, low platelet counts, or diabetes in those infants.24PubMed Central. Use of diuretics during pregnancy This does not mean triamterene/HCTZ is recommended during pregnancy. It means that women who become pregnant while on the drug should not panic but should work with their doctor to switch to a medication with a better-established pregnancy safety profile, typically methyldopa or labetalol.
An Unexpected Use for Inner-Ear Vertigo
Ménière’s disease causes episodes of intense vertigo, hearing loss, and ringing in the ears. The standard first-line recommendation is salt restriction and a diuretic, with the idea that reducing fluid volume in the inner ear will ease pressure on the delicate structures that control balance and hearing. Triamterene/HCTZ (sold as Dyazide) was tested in a double-blind crossover trial against placebo in 33 Ménière’s patients. It had no significant effect on hearing or tinnitus, but the vestibular complaints, meaning the dizziness and vertigo attacks, decreased significantly during the treatment phase. More than half of the patients preferred the active drug over placebo.25PubMed. Use of a diuretic (Dyazide) in the treatment of Menière’s disease. A double-blind cross-over placebo-controlled study It is a narrow and somewhat dated evidence base, but it explains why you may still see this combination prescribed for vertigo-dominant Ménière’s disease.
Why a Single Pill Matters for Adherence
A fixed-dose combination pill bundles two drugs into one daily tablet. That sounds like a trivial convenience until you consider how reliably people actually take their medications. Reviews of fixed-dose combination therapy in hypertension have consistently found that putting two agents in one tablet improves adherence compared to taking the same two drugs as separate pills, and also tends to lower overall healthcare costs by reducing pharmacy fills and simplifying regimens.26PubMed. Using fixed-dose combination therapies to achieve blood pressure goals For a drug like triamterene/HCTZ, where the entire rationale depends on the two components working in concert, a fixed-dose tablet ensures that patients do not accidentally take the HCTZ and skip the potassium-sparing partner, which would defeat the purpose of the combination in the first place.
Generic versions of triamterene/HCTZ are among the least expensive blood pressure medications available, often costing only a few dollars per month without insurance. For patients who need simple, inexpensive blood pressure control with built-in potassium protection, the combination remains a sensible first-line or second-line option, even as flashier drugs draw more attention in treatment guidelines.